Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.
There is a continuing search for better ways to use existing drugs against human immunodeficiency virus (HIV). One idea is to use short therapy interruptions to "autovaccinate" HIV-infected patients. A group of 13 chronically HIV-infected patients enrolled in a trial of such so-called stru...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2002
|
| _version_ | 1797069640158937088 |
|---|---|
| author | Oxenius, A Mclean, A Fischer, M Price, D Dawson, S Hafner, R Schneider, C Joller, H Hirschel, B Phillips, R Weber, R Günthard, H |
| author_facet | Oxenius, A Mclean, A Fischer, M Price, D Dawson, S Hafner, R Schneider, C Joller, H Hirschel, B Phillips, R Weber, R Günthard, H |
| author_sort | Oxenius, A |
| collection | OXFORD |
| description | There is a continuing search for better ways to use existing drugs against human immunodeficiency virus (HIV). One idea is to use short therapy interruptions to "autovaccinate" HIV-infected patients. A group of 13 chronically HIV-infected patients enrolled in a trial of such so-called structured treatment interruptions (STIs) were intensively studied with respect to their viral load (VL) and HIV-specific CD8+ T-cell (cytotoxic T-lymphocyte [CTL]) responses. We found that 10 of the 13 patients had plateau VLs after STIs that were lower than their pretreatment VLs. While viral rebound rates became lower over STIs, there were no changes in clearance rates. Although numbers of CTLs did increase over the same time that viral rebounds decreased, there was no correlation between CTL count and either viral rebound rates or clearance rates. Finally, we asked whether absolute numbers of or changes in numbers of CTLs predict plateau VLs after STIs. No measure of CTLs was able to predict plateau VLs. Thus, there was no signature in these data of an important contribution to virological control from HIV-specific CD8+ T lymphocytes. |
| first_indexed | 2024-03-06T22:27:27Z |
| format | Journal article |
| id | oxford-uuid:572185b1-0674-4eff-ad10-944c4ef85259 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:27:27Z |
| publishDate | 2002 |
| record_format | dspace |
| spelling | oxford-uuid:572185b1-0674-4eff-ad10-944c4ef852592022-03-26T16:54:47ZHuman immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:572185b1-0674-4eff-ad10-944c4ef85259EnglishSymplectic Elements at Oxford2002Oxenius, AMclean, AFischer, MPrice, DDawson, SHafner, RSchneider, CJoller, HHirschel, BPhillips, RWeber, RGünthard, HThere is a continuing search for better ways to use existing drugs against human immunodeficiency virus (HIV). One idea is to use short therapy interruptions to "autovaccinate" HIV-infected patients. A group of 13 chronically HIV-infected patients enrolled in a trial of such so-called structured treatment interruptions (STIs) were intensively studied with respect to their viral load (VL) and HIV-specific CD8+ T-cell (cytotoxic T-lymphocyte [CTL]) responses. We found that 10 of the 13 patients had plateau VLs after STIs that were lower than their pretreatment VLs. While viral rebound rates became lower over STIs, there were no changes in clearance rates. Although numbers of CTLs did increase over the same time that viral rebounds decreased, there was no correlation between CTL count and either viral rebound rates or clearance rates. Finally, we asked whether absolute numbers of or changes in numbers of CTLs predict plateau VLs after STIs. No measure of CTLs was able to predict plateau VLs. Thus, there was no signature in these data of an important contribution to virological control from HIV-specific CD8+ T lymphocytes. |
| spellingShingle | Oxenius, A Mclean, A Fischer, M Price, D Dawson, S Hafner, R Schneider, C Joller, H Hirschel, B Phillips, R Weber, R Günthard, H Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. |
| title | Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. |
| title_full | Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. |
| title_fullStr | Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. |
| title_full_unstemmed | Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. |
| title_short | Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. |
| title_sort | human immunodeficiency virus specific cd8 t cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy |
| work_keys_str_mv | AT oxeniusa humanimmunodeficiencyvirusspecificcd8tcellresponsesdonotpredictviralgrowthandclearanceratesduringstructuredintermittentantiretroviraltherapy AT mcleana humanimmunodeficiencyvirusspecificcd8tcellresponsesdonotpredictviralgrowthandclearanceratesduringstructuredintermittentantiretroviraltherapy AT fischerm humanimmunodeficiencyvirusspecificcd8tcellresponsesdonotpredictviralgrowthandclearanceratesduringstructuredintermittentantiretroviraltherapy AT priced humanimmunodeficiencyvirusspecificcd8tcellresponsesdonotpredictviralgrowthandclearanceratesduringstructuredintermittentantiretroviraltherapy AT dawsons humanimmunodeficiencyvirusspecificcd8tcellresponsesdonotpredictviralgrowthandclearanceratesduringstructuredintermittentantiretroviraltherapy AT hafnerr humanimmunodeficiencyvirusspecificcd8tcellresponsesdonotpredictviralgrowthandclearanceratesduringstructuredintermittentantiretroviraltherapy AT schneiderc humanimmunodeficiencyvirusspecificcd8tcellresponsesdonotpredictviralgrowthandclearanceratesduringstructuredintermittentantiretroviraltherapy AT jollerh humanimmunodeficiencyvirusspecificcd8tcellresponsesdonotpredictviralgrowthandclearanceratesduringstructuredintermittentantiretroviraltherapy AT hirschelb humanimmunodeficiencyvirusspecificcd8tcellresponsesdonotpredictviralgrowthandclearanceratesduringstructuredintermittentantiretroviraltherapy AT phillipsr humanimmunodeficiencyvirusspecificcd8tcellresponsesdonotpredictviralgrowthandclearanceratesduringstructuredintermittentantiretroviraltherapy AT weberr humanimmunodeficiencyvirusspecificcd8tcellresponsesdonotpredictviralgrowthandclearanceratesduringstructuredintermittentantiretroviraltherapy AT gunthardh humanimmunodeficiencyvirusspecificcd8tcellresponsesdonotpredictviralgrowthandclearanceratesduringstructuredintermittentantiretroviraltherapy |